Triumvira is co-opting native T cell receptors to create safer CAR T therapies
CAR T therapies have produced profound responses in hematological cancers, but also severe toxicities such as cytokine release syndrome. Triumvira Immunologics Inc.’s T Cell-Antigen Coupler platform combines the specificity of chimeric antigen receptors with the native regulatory mechanisms of T cell receptors to reduce the risk of cytokine-related toxicities.
The biotech’s T Cell-Antigen Couplers (TACs) accomplish this by signaling through the TCR complex.
A typical CAR comprises an extracellular antigen-specific domain fused to a transmembrane domain and at least one intracellular co-stimulatory